Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQL ArQule	$20.00	$20.00	$3.15 ▼ $20.45	$2.42B	2.49	5.27 million shs	N/A
EXAS Exact Sciences	$46.68 -0.7%	$49.83	$38.81 ▼ $72.83	$8.84B	0.93	2.80 million shs	2.14 million shs
HALO Halozyme Therapeutics	$71.61 +0.7%	$58.02	$42.01 ▼ $72.33	$8.38B	1.17	1.96 million shs	1.86 million shs
MDGL Madrigal Pharmaceuticals	$407.09 +3.9%	$316.47	$200.63 ▼ $414.50	$9.04B	-1.02	382,203 shs	594,115 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQL ArQule	0.00%	0.00%	0.00%	0.00%	0.00%
EXAS Exact Sciences	+2.89%	+4.65%	-2.81%	-16.78%	-20.10%
HALO Halozyme Therapeutics	+1.64%	+9.21%	+27.20%	+32.33%	+16.74%
MDGL Madrigal Pharmaceuticals	+3.19%	+4.87%	+18.35%	+43.28%	+51.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQL ArQule	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EXAS Exact Sciences	4.9139 of 5 stars	4.5	5.0	0.0	4.7	3.7	2.5	0.6
HALO Halozyme Therapeutics	4.673 of 5 stars	2.1	1.0	0.0	4.4	4.0	2.5	4.4
MDGL Madrigal Pharmaceuticals	4.0393 of 5 stars	2.4	0.0	0.0	4.6	3.7	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQL ArQule	0.00	N/A	N/A	N/A
EXAS Exact Sciences	2.92	Moderate Buy	$67.43	44.45% Upside
HALO Halozyme Therapeutics	2.18	Hold	$67.11	-6.28% Downside
MDGL Madrigal Pharmaceuticals	2.88	Moderate Buy	$445.71	9.49% Upside

Current Analyst Ratings Breakdown

Latest ARQL, MDGL, HALO, and EXAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$483.00 ➝ $485.00
8/18/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$75.00 ➝ $80.00
8/12/2025	EXAS Exact Sciences	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $60.00
8/12/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$458.00 ➝ $523.00
8/11/2025	EXAS Exact Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$70.00 ➝ $60.00
8/8/2025	EXAS Exact Sciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $64.00
8/7/2025	EXAS Exact Sciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	EXAS Exact Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$61.00 ➝ $53.00
8/7/2025	EXAS Exact Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$54.00 ➝ $46.00
8/7/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
8/7/2025	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$60.00 ➝ $63.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQL ArQule	$25.76M	93.85	N/A	N/A	$0.72 per share	27.78
EXAS Exact Sciences	$2.76B	3.20	$5.76 per share	8.11	$13.04 per share	3.58
HALO Halozyme Therapeutics	$1.02B	8.25	$4.76 per share	15.04	$2.84 per share	25.21
MDGL Madrigal Pharmaceuticals	$180.13M	50.17	N/A	N/A	$31.35 per share	12.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQL ArQule	-$15.48M	-$0.16	N/A	N/A	N/A	-805.61%	-33.10%	-26.87%	N/A
EXAS Exact Sciences	-$1.03B	-$5.43	N/A	93.36	4.67	-34.19%	-1.75%	-0.76%	11/4/2025 (Estimated)
HALO Halozyme Therapeutics	$444.09M	$4.37	16.39	11.51	0.38	47.28%	150.85%	29.19%	10/30/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$12.85	N/A	N/A	N/A	-54.68%	-38.38%	-27.32%	10/30/2025 (Estimated)

Latest ARQL, MDGL, HALO, and EXAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EXAS Exact Sciences	-$0.02	$0.22	+$0.24	-$0.01	$774.43 million	$811.09 million
8/5/2025	Q2 2025	HALO Halozyme Therapeutics	$1.23	$1.54	+$0.31	$1.33	$282.66 million	$325.72 million
8/5/2025	Q2 2025	MDGL Madrigal Pharmaceuticals	-$3.48	-$1.90	+$1.58	-$1.90	$158.94 million	$212.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQL ArQule	N/A	N/A	N/A	N/A	N/A
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQL ArQule	0.08	8.27	8.27
EXAS Exact Sciences	0.94	2.89	2.56
HALO Halozyme Therapeutics	4.54	8.36	7.01
MDGL Madrigal Pharmaceuticals	0.17	5.11	4.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQL ArQule	74.63%
EXAS Exact Sciences	88.82%
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
ARQL ArQule	13.80%
EXAS Exact Sciences	1.20%
HALO Halozyme Therapeutics	2.40%
MDGL Madrigal Pharmaceuticals	21.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQL ArQule	36	120.87 million	N/A	Optionable
EXAS Exact Sciences	7,000	189.32 million	187.05 million	Optionable
HALO Halozyme Therapeutics	390	116.97 million	114.16 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable

ARQL, MDGL, HALO, and EXAS Headlines

Recent News About These Companies

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

2 hours ago | globenewswire.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Bros. Advisors Lp Baker Acquires 59,901 Shares

August 21 at 7:28 AM | insidertrades.com

Groupama Asset Managment Purchases 9,128 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

August 21 at 6:37 AM | marketbeat.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 1-Year High - Here's Why

August 21 at 5:08 AM | marketbeat.com

Russell Investments Group Ltd. Has $9.80 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGL

August 21 at 3:59 AM | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Brokerages

August 21 at 2:38 AM | marketbeat.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) General Counsel Sells $479,624.24 in Stock

August 20 at 8:44 PM | marketbeat.com

Madrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMP

August 20 at 6:52 PM | msn.com

Madrigal gets EU nod for its MASH treatment

August 20 at 6:52 PM | msn.com

Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU

August 20 at 1:45 PM | zacks.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down Following Insider Selling

August 20 at 10:32 AM | marketbeat.com

Madrigal Shares Slip After FDA Clears Novo Nordisk’s Wegovy for MASH

August 20 at 2:47 AM | msn.com

Madrigal gets conditional marketing authorization for Rezdiffra from EC

August 20 at 2:47 AM | msn.com

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

August 20 at 2:47 AM | finance.yahoo.com

Madrigal Receives European Commission Approval for Rezdiffraâ„¢ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

August 19 at 4:19 PM | globenewswire.com

Invesco Ltd. Purchases 3,860 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

August 19 at 4:31 AM | marketbeat.com

Shannon T. Kelley Sells 1,304 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock

August 19 at 4:27 AM | insidertrades.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down on Insider Selling

August 19 at 2:13 AM | americanbankingnews.com

Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH

August 18 at 12:46 AM | finance.yahoo.com

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

August 18 at 12:46 AM | msn.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Increased by Sei Investments Co.

August 18 at 5:34 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQL, MDGL, HALO, and EXAS Company Descriptions

ArQule NASDAQ:ARQL

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Exact Sciences NASDAQ:EXAS

$46.68 -0.32 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$46.80 +0.13 (+0.27%)

As of 04:53 PM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Halozyme Therapeutics NASDAQ:HALO

$71.61 +0.48 (+0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$72.40 +0.79 (+1.10%)

As of 05:15 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$407.09 +15.43 (+3.94%)

Closing price 04:00 PM Eastern

Extended Trading

$402.44 -4.65 (-1.14%)

As of 05:07 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time